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Predictors of chronic opioid therapy
in Medicaid beneficiaries with HIV
who initiated antiretroviral therapy
GYeon Oh1,2,3, Emily S. Brouwer2,4, Erin L. Abner1,5,6, David W. Fardo5,6,
Patricia R. Freeman2,3, Chris Delcher2,3 & Daniela C. Moga1,2,3,5*
The factors associated with chronic opioid therapy (COT) in patients with HIV is understudied. Using
Medicaid data (2002–2009), this retrospective cohort study examines COT in beneficiaries with HIV
who initiated standard combination anti-retroviral therapy (cART). We used generalized estimating
equations on logistic regression models with backward selection to identify significant predictors
of COT initiation. COT was initiated among 1014 out of 9615 beneficiaries with HIV (male: 10.4%;
female: 10.7%). Those with older age, any malignancy, Hepatitis C infection, back pain, arthritis,
neuropathy pain, substance use disorder, polypharmacy, (use of) benzodiazepines, gabapentinoids,
antidepressants, and prior opioid therapies were positively associated with COT. In sex-stratified
analyses, multiple predictors were shared between male and female beneficiaries; however, chronic
obstructive pulmonary disease, liver disease, any malignancy, and antipsychotic therapy were
unique to female beneficiaries. Comorbidities and polypharmacy were important predictors of COT in
Medicaid beneficiaries with HIV who initiated cART.
In the US, an estimated 39% to 90% of patients with HIV report chronic p
 ain1–6, including general pain, such as
head, leg, and back pain; neuropathic pain; and Kaposi sarcoma-related p
 ain1. About one-half of these patients
6
are prescribed opioid analgesics . The prevalence of high-dose opioid prescribing is higher in patients with HIV
compared to the general p
 opulation7,8, and initiation of chronic opioid therapy (COT) was reported to be 1.5
times higher in opioid-naïve people living with HIV compared to those without HIV, after adjusting for demographics and comorbidities9. However, several studies have reported that COT confers risks, such as opioid abuse
or dependence10–12 and p
 oisoning13. Especially among patients with HIV, an increased risk of mortality has been
reported for those on C
 OT14 and high opioid d
 oses15.
Although one-quarter of patients with HIV in the US are w
 omen16, the majority of people included in
observational studies examining the association between prescribing opioids and HIV status were men
(78.8–98%)2,7,8,17,18. However, descriptive studies suggest that women with HIV suffer from more severe pain6
and are prescribed more o
 pioids19 compared to men with HIV. Moreover, a longitudinal study reported that
among patients with HIV, COT was more common among female participants than “never or sporadic [opioid]
use”20. Thus, inclusion of both men and women is crucial when assessing prescription opioid therapy and related
health concerns in patients with HIV.
Therefore, this study aimed to (1) examine the prevalence of COT in Medicaid beneficiaries with HIV; (2)
understand the characteristics of patients with HIV who initiate COT; and (3) investigate whether there are
sex-specific factors associated with COT among Medicaid beneficiaries with HIV after standard combination
anti-retroviral therapy (cART) initiation.

Methods

Data source and study population. Medicaid administrative data (2002–2009), obtained from the Centers for Medicaid and Medicare Services, was used for this study. In 2009, 41% of nonelderly adults with HIV in
care was covered by Medicaid, which was the largest source of insurance c overage21. Beneficiaries may become
Medicaid-eligible through several mechanisms, which may depend on the state of residence. Generally, the criteria of Medicaid eligibility are based on low income, pregnancy, and disabilities. This study included the Medicaid
1
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Analytic eXtract (MAX) personal summary file (PS), inpatient (IP), prescription (RX), and other services (OT)
from four states––Kentucky (KY), Maryland (MD), North Carolina (NC), and Washington (WA). These four
states represent different HIV populations during the years of the study––patients with HIV in Maryland are
more likely to have acquired HIV through intravenous drug user (IVDU)22; Washington has a high proportion
of people living with HIV who are men who have sex with men (MSM)23; North Carolina has a high proportion of heterosexual patients with HIV24; and Kentucky is one of the states with low prevalence and morbidity
of HIV25.
We included patients with HIV defined as those who filled prescriptions for standard cART on the same date
(i.e., cohort entry date) for at least seven days’ supply among Medicaid eligible beneficiaries between 2002 and
2009. Standard cART regimens included two nucleoside reverse transcriptase inhibitors (NRTIs) with either a
non-nucleoside reverse transcriptase inhibitor (NNRTI), integrase strand transfer inhibitor (INSTI), or protease
inhibitor (PI). The drug name and class were identified from the Medicaid data using national drug codes (NDC)
linked with Medispan Generic Product Identifiers (GPI). Inclusion criteria included: (1) age 18–65 years at the
cohort entry date; (2) continuous eligibility for at least 180 days prior to the cohort entry date, allowing a onemonth gap (i.e., washout period). We excluded beneficiaries who (1) had less than six-months between enrollment and standard cART regimen start date; (2) had COT during the washout period; or (3) had no medical
or prescription claim during the washout period. Patient follow-up time was the interval from cART initiation
until the earliest of: (1) loss of Medicaid eligibility for > 31 days when multiple enrollments occurred; (2) end of
the study period (December 31, 2009). The guideline from CDC defined COT as use of opioids on most days for
more than three m
 onths26; however, there is no standard definition of C
 OT27. Several different definitions have
been used [e.g., (1) 90 days of continuous use; (2) longer than 90 days use with either 120 + total days of supply
or 10 or more prescriptions dispensed in a year; and (3) 90 days of continuous use (accepting ≤ 32 days of the
prescription gap), with multiple opioid prescription claims in a six months period] in different s tudies2,19,28. In
this study, COT was defined as at least 90 days of continuous opioid analgesic treatment (accepting ≤ 32 days of
the prescription gap), with multiple opioid prescription claims in a six months p
 eriod28–30. Opioid analgesics
were identified using NDC linked with Medispan GPI (starting with ‘65’).

Potential predictors.

Demographic variables, including age, sex, race, and state of residence, were assessed
at the cohort entry date. Age was calculated at cohort entry year based on beneficiaries’ date of birth using PS
files. International Classification of Disease, 9th Clinical Modification (ICD-9-CM) codes were used based on
existing validated definitions31–35 listed anywhere in the IP and OP files to identify beneficiaries’ medical history, and NDCs were used to identify use of medications. Medical history, including diagnoses of cardiovascular disease, hypertension, dementia, chronic obstructive pulmonary disease (COPD), liver disease, diabetes,
renal disease, any malignancy (including lymphoma and leukemia, except malignant neoplasm skin), metastatic
solid tumor, substance use disorder, Hepatitis C infection, depression, psychotic disorder, back pain, neck pain,
arthritis, migraine, opportunistic infection, tobacco use, neuropathy pain, unclassified pain, any fracture, and
surgery history, were identified during the washout period. From the RX file, use of medications, including any
opioid use, benzodiazepine, gabapentinoid, non-opioid pain medication, including analgesic-anti-inflammatory
(GPI starting with ‘66’) and analgesic-nonnarcotic (GPI starting with ‘64’), antidepressant, and antipsychotic
were identified during the washout period. Also, polypharmacy, defined as using 5 or more different medications
exclusive of the cART regimen, was identified at the cohort entry date. A detailed description of the variables
considered in the analysis is included in Table S1.

Statistical analysis. Baseline characteristics of the beneficiaries included in this analysis were summarized

using the mean with standard deviation (SD) for age, median with interquartile range (IQR) for follow-up days,
and frequencies with percentages for categorical variables. We used t-tests and Pearson chi-square tests to assess
differences between beneficiaries who initiated COT and those who did not. To identify predictors of COT in
beneficiaries with HIV who initiated standard cART, we used generalized estimating equations (GEE) with an
exchangeable working correlation structure on multivariable logistic regressions to account for within-state correlations among beneficiaries. The final reduced models were fit by backward selection with manually removing
the variables with the largest p-value until reaching to the lowest Quasi Information Criterion (QIC). Additionally, multivariable logistic regression models with backward selection (without accounting for state clustering),
least absolute shrinkage and selection operator (LASSO) regression using backward selection with the Schwarz
Bayesian Information Criterion (SBC)36,37, and elastic net logistic regression with cross-validation were used to
assess the robustness of the factors identified. Stratified analyses were used to investigate sex-specific predictors of COT. GEE multivariable logistic regression with backward selection was used to identify sex-specific
factors associated with COT. Also, multivariable logistic regression models and LASSO regression with SBC
using backward selections and elastic net logistic regression model with cross-validation were used to examine
the robustness of the sex-specific factors. Adjusted odds ratios (ORadj) with 95% confidence intervals (CI) were
obtained from the full and reduced models. All data analyses were conducted using SAS 9.4®, and 0.05 was set as
the significance level. The study was approved by the University of Kentucky Institutional Review Board (IRB)
and the same IRB granted waiver of informed consent due to the nature of the data. All methods were carried
out in accordance with relevant guidelines and regulations.

Results

In this study, 9,615 Medicaid beneficiaries (mean [SD] age: 41 [10.2] years) with HIV who initiated standard
cART were included after applying inclusion and exclusion criteria (Fig. 1). The median (IQR) follow-up years for
this sample was 2.15 (0.81–4.48) years and the majority of beneficiaries were male (53.6%) (Table 1). Among the
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Figure 1.  Sample selection flowchart.

final sample of beneficiaries with HIV (N = 9615), a total of 1,014 beneficiaries (10.5%) initiated COT. The median
(IQR) follow-up years was longer in COT initiators (4.06 [2.37–5.84] years) compared to non-initiators (1.90
[0.72–4.24] years). COT initiators were older (43.5 years vs. 40.7 years, p-value: < 0.0001), more likely to be white
(vs. black) race (26.1% vs. 19.1%, p-value: < 0.0001), and had more baseline comorbidities than non-initiators.
The most common comorbidities among COT initiators was arthritis and joint pain (final sample: 20.5%; COT:
30.5%; no COT: 19.4%). Polypharmacy was more common among COT initiators than non-initiators (16%
vs. 9.4%), and half of COT initiators filled at least one opioid analgesic prescription prior to entering the study
(50.9%), whereas approximately 30% of non-initiators filled at least one opioid analgesic prescription (Table 1).

Predictors of chronic opioid use. The full model, including all variables are listed in the Table 1, and the

reduced model using GEE multivariable logistic regressions are reported in Table 2. Several factors emerged as
significant predictors positively associated with COT initiation: age, medical diagnoses (COPD, any malignancy,
Hepatitis C infection, opportunistic infection, substance use disorder, back pain, arthritis, neuropathy pain), and
use of medications (non-opioid pain medication, benzodiazepine, gabapentinoid, antidepressant, antipsychotic,
any opioid, 5 + medication vs. none, 1–4 medications vs. none). Several factors were negatively associated with
COT initiation: race (black vs. white; other vs. white) and medical diagnoses (cardiovascular disease, diabetes,
psychotic disorder, any fracture, tobacco use disorder, and alcohol abuse) (Table 2).
The reduced model without accounting for clustering within states reported similar O
 Radj with 95% CI, but
diabetes, any malignancy, any fracture, opportunistic infection, alcohol abuse, tobacco use disorder, arthritis, COPD, and use of antipsychotic medications were not included in the reduced model without clustering
(Table S2). Another reduced model using LASSO reported similar O
 Radj with 95% CI, but factors, including
diabetes, any malignancy, any fracture, opportunistic infection, alcohol abuse, tobacco use disorder, cardiovascular disease, psychotic disorder, and antipsychotic medications were not in the reduced model using LASSO
(Table S2). The predictors included in the reduced model using elastic net with cross-validation were more similar
to the final model, but having diabetes, opportunistic infection, tobacco use disorder, and antipsychotics were
not included (Table S2). After selecting factors by LASSO and elastic net, the factors were entered into the GEE
multivariable logistic regression accounting for clustering within states. Thus, considering state as a significant
clustering factor in this study, GEE multivariable logistic regression models were selected as our final model.

Characteristics of the beneficiaries by sex.

Female beneficiaries were on average younger than males
(mean [SD] age 39.0 [10.4] vs. 42.7 [9.6] years, respectively, p-value: < 0.0001), and the median [IQR] follow-up
days was slightly longer (p-value: < 0.0001) in females (801 [307.5–1624)) than males (759 [287–1646)). The
most common comorbidity in both sexes was arthritis and joint pain (male: 20.2%; female: 20.9%). Male beneficiaries had a higher percentage of polypharmacy (11.1%) than females (8.9%) (Table 3).
Among male beneficiaries, the most common comorbidities were arthritis and joint pain for both COT initiators (30.5%) and non-initiators (19%). Antidepressant medication therapy was common for both COT initiators
(35%) and non-initiators (23%). Almost half of the male beneficiaries who initiated COT (48.6%) filled a prescription for any opioid during the washout period. Among female beneficiaries, the most common comorbidity was
substance use disorder (33.0%) for COT initiators and arthritis and joint pain (19.8%) for non-initiators. Almost
half of the female COT initiators filled a prescription for antidepressants (45.2%), whereas 27.3% of female noninitiators filled a prescription for antidepressants. Over half of the female beneficiaries (53.4%) who initiated
COT filled a prescription for opioids during the washout period (Table 3). For most pain-related symptoms, no
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p-value

Total (N = 9615)

Chronic opioid users (N = 1014)

No chronic opioid users (N = 8601)

Age, mean (SD)

41.0 (10.2)

43.5 (7.6)

40.7 (10.4)

< 0.0001

Female

4460 (46.4)

476 (47.0)

3986 (46.3)

0.69
< 0.0001

Race
White

1911 (19.9)

265 (26.1)

1646 (19.1)

Black

7057 (73.4)

686 (67.7)

6371 (74.1)

Othera

266 (2.8)

23 (2.3)

243 (2.8)

Unknown

381 (4.0)

40 (3.9)

341 (4.0)

State
Kentucky

407 (4.2)

Maryland

4573 (47.6)

508 (50.1)

40 (3.9)

4065 (47.3)

367 (4.3)

North Carolina

3589 (37.3)

334 (32.9)

3255 (37.8)

Washington

1046 (10.9)

132 (13.0)

914 (10.6)

0.006

Comorbidities
Cardiovascular disease

913 (9.5)

111 (11.0)

802 (9.3)

Hypertension

1727 (18.0)

236 (23.3)

1491 (17.3)

< 0.0001

Dementia

161 (1.7)

140 (1.6)

0.30

COPD

1332 (13.9)

192 (18.9)

1140 (13.3)

< 0.0001

Any liver disease

995 (10.4)

161 (15.9)

834 (9.7)

< 0.0001

21 (2.1)

0.10

Diabetes

695 (10.4)

89 (8.8)

606 (7.1)

0.04

Renal disease

536 (5.6)

65 (6.4)

471 (5.5)

0.22

Any malignancy

377 (3.9)

59 (5.8)

318 (3.7)

0.001

59 (0.6)

12 (1.2)

47 (0.6)

0.014

Hepatitis C infection

1069 (11.1)

196 (19.3)

873 (10.2)

< 0.0001

Depression

1750 (18.2)

239 (23.6)

1511 (17.6)

< 0.0001

Metastatic solid tumor

Psychotic disorder

626 (6.5)

69 (6.8)

557 (6.5)

0.69

Migraine/headache

123 (1.3)

14 (1.4)

109 (1.3)

0.76

Any fracture

209 (2.2)

25 (2.5)

184 (2.1)

0.50

Surgery history

105 (1.1)

13 (1.3)

92 (1.1)

0.54

Opportunistic infection

1863 (19.4)

234 (23.1)

1629 (18.9)

0.002

Alcohol abuse

814 (8.5)

104 (10.3)

710 (8.3)

0.03

Substance use disorder

1850 (19.2)

302 (29.8)

1548 (18.0)

< 0.0001

Tobacco use disorder

834 (8.7)

109 (10.8)

725 (8.4)

0.013

Pain-related disorder
Back pain

790 (8.2)

153 (15.1)

637 (7.4)

< 0.0001

Neck pain

277 (2.9)

45 (4.4)

232 (2.7)

0.002

Arthritis/joint pain

1973 (20.5)

309 (30.5)

1664 (19.4)

< 0.0001

Neuropathy pain

938 (9.8)

163 (16.1)

775 (9.0)

< 0.0001

Unclassified pain

413 (4.3)

62 (6.1)

351 (4.1)

0.003
< 0.0001

Number of medications
None

3536 (36.8)

289 (28.5)

3247 (37.8)

1–4

5113 (53.2)

563 (55.5)

4550 (52.9)

5+

966 (10.1)

162 (16.0)

804 (9.4)

Non-opioid Pain medication

2284 (23.8)

336 (33.1)

1948 (22.7)

< 0.0001

Benzodiazepine

940 (9.8)

191 (18.8)

749 (8.7)

< 0.0001

Gabapentinoid

576 (6.0)

114 (11.2)

462 (5.4)

< 0.0001

Antidepressant

2550 (26.5)

403 (39.7)

2147 (25.0)

< 0.0001

Antipsychotics

1242 (12.9)

180 (17.8)

1062 (12.4)

< 0.0001

Any opioid use

3050 (31.7)

516 (50.9)

2534 (29.5)

< 0.0001

Table 1.  Characteristics of study sample. Abbreviation: COPD, Chronic pulmonary disease; COT, Chronic
opioid therapy. All results presented are N (%) unless otherwise noted. a American Indian, Alaskan Native,
Hispanic, Asian, Pacific Islander, Native Hawaiian, more than one race.

significant differences in the prevalence between males and females were observed (back pain [p = 0.88], neck
pain [p = 0.76], arthritis and joint pain [p = 0.38], and neuropathic pain [p = 0.90]). However, higher prevalence
of unclassified pain (6.5% vs. 2.4%, p < 0.0001) and migraine/headache (1.6% vs. 1.0%, p = 0.004) were observed
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Full Model ORadj (95% CI)

Reduced Model ORadj (95% CI)

Age

1.02 (1.01 1.03)

1.02 (1.01, 1.03)

Female

1.06 (0.82, 1.37)

Race
Black vs. white

0.76 (0.62, 0.93)

Othera vs. white

0.67 (0.58, 0.79)

0.77 (0.65, 0.91)
0.68 (0.59, 0.78)

Unknown vs. white

0.82 (0.67, 1.01)

0.84 (0.67, 1.05)
0.77 (0.68, 0.88)

Comorbidities
Cardiovascular disease

0.78 (0.64, 0.96)

Hypertension

1.11 (0.95, 1.30)

Dementia

0.89 (0.58, 1.36)

COPD

1.16 (0.90, 1.50)

Any liver disease

0.93 (0.74, 1.16)

Diabetes

0.91 (0.78, 1.05)

Renal disease

0.85 (0.58, 1.25)

Any malignancy

1.26 (1.18, 1.35)

Metastatic solid tumor

1.10 (0.67, 1.83)

Hepatitis C infection

1.62 (1.41, 1.87)

Depression

0.98 (0.75, 1.30)

Psychotic disorder

0.71 (0.63, 0.80)

Migraine/headache

0.86 (0.61, 1.21)

Any fracture

0.70 (0.57, 0.87)

Surgery history

1.04 (0.77, 1.39)

1.18 (0.92, 1.51)
0.92 (0.82, 1.02)
1.28 (1.23, 1.33)
1.55 (1.47, 1.64)
0.70 (0.62, 0.79)
0.70 (0.55, 0.89)

Opportunistic infection

1.05 (0.98, 1.13)

1.04 (0.98, 1.11)

Alcohol abuse

0.85 (0.69, 1.03)

0.84 (0.66, 1.05)

Substance use disorder

1.62 (1.22, 2.16)

1.62 (1.25, 2.12)

Tobacco use disorder

0.86 (0.74, 1.00)

0.86 (0.78, 1.02)

Back pain

1.44 (1.11, 1.88)

1.46 (1.10, 1.93)

Neck pain

1.02 (0.88, 1.17)

Arthritis

1.11 (0.98, 1.26)

1.13 (1.01, 1.25)

Neuropathy pain

1.18 (1.05, 1.33)

1.17 (1.05, 1.30)

Unclassified pain

1.04 (0.91, 1.20)

Number of medications
1–4 medications vs. none

1.35 (1.29, 1.41)

1.34 (1.29, 1.40)

5 + medications vs. none

1.73 (1.44, 2.08)

1.71 (1.40, 2.09)

Non-opioid pain medication

1.15 (0.94, 1.41)

1.16 (0.96, 1.40)

Benzodiazepine

1.62 (1.49, 1.76)

1.62 (1.48, 1.77)

Gabapentinoid

1.33 (1.21, 1.46)

1.33 (1.21, 1.45)

Antidepressant

1.31 (1.06, 1.62)

1.31 (1.10, 1.56)

Antipsychotic

1.09 (0.96, 1.24)

1.09 (0.99, 1.21)

Any opioid use

1.85 (1.59, 2.15)

1.86 (1.61, 2.13)

Table 2.  Predictors of chronic opioid use vs. no chronic opioid use in Medicaid beneficiaries with HIV.
a
American Indian, Alaskan Native, Hispanic, Asian, Pacific Islander, Native Hawaiian, more than one race.
Abbreviation COPD, Chronic pulmonary disease. Note Generalized estimate equation multivariable logistic
regressions, accounting for clustering at the state level, were used and the reduced model was selected by
backward selection.

in females (Table 3). There was no statistically significant difference (p-value: 0.69) in the prevalence of COT
between females (10.4%) and males (10.7%). The COT prevalence was significantly higher in female beneficiaries
in MD (male vs. female: 10.1% vs. 12.1%, p-value: 0.03). However, no statistically significant differences were
observed in the other three states (male vs. female, KY: 12.4% vs. 6.6%, p-value: 0.052; NC: 9.4% vs. 9.3%, p-value:
0.92; and WA: 13.3% vs. 10.2%, p-value: 0.19).

Predictors of COT by sex. The predictors of COT (reduced model) in females and males, accounting
for within-state correlation, are presented in Fig. 2. The sex-specific full and reduced models with and without
accounting for within-state correlation are presented in Tables S3 and S4. Many factors associated with COT
were not sex-specific (age; race; having cardiovascular disease, hypertension, renal disease, metastatic solid
tumor, Hepatitis C infection, psychotic disorder, any fracture, surgery history, substance use disorder, tobacco
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Male (N = 5154)
Total (N = 5154)
Age, mean (SD)

Female (N = 4460)
Chronic opioid users
(N = 537)

No chronic opioid
users (N = 4617)

Total (N = 4460)

Chronic opioid users
(N = 476)

No chronic opioid
users (N = 3984)

42.7 (9.6)

44.3 (7.3)

42.5 (9.9)

39.0 (10.4)

42.5 (7.8)

38.6 (10.6)

White

1,264 (24.5)

162 (30.2)

1,102 (23.9)

646 (14.5)

102 (21.4)

544 (16.7)

3540 (79.4)

Race
Black

3517 (68.2)

338 (62.9)

3179 (68.9)

348 (73.1)

3192 (80.1)

141 (2.7)

15 (2.8)

126 (2.7)

125 (2.8)

8 (1.7)

117 (2.9)

Unknown

232 (4.5)

22 (4.1)

210 (4.6)

149 (3.3)

18 (3.8)

131 (3.3)

226 (4.4)

28 (5.2)

198 (4.3)

181 (4.1)

12 (2.5)

169 (4.2)

State

< 0.0001

Maryland

2300 (44.6)

232 (43.2)

2068 (44.8)

2273 (51.0)

276 (58.0)

1,997 (50.1)

North Carolina

1839 (35.7)

172 (32.0)

1667 (36.1)

1750 (39.2)

162 (34.0)

1588 (39.9)

789 (15.3)

105 (19.6)

684 (14.8)

256 (5.7)

26 (5.5)

230 (5.8)

Washington

< 0.0001
< 0.0001

Otherb

Kentucky

p-valuea

Comorbidities
Cardiovascular disease

525 (10.2)

61 (11.4)

464 (10.1)

388 (8.7)

50 (10.5)

338 (8.5)

0.01

Hypertension

882 (17.1)

113 (21.0)

769 (16.7)

845 (19.0)

123 (25.8)

722 (18.1)

0.02

Dementia

104 (2.0)

14 (2.6)

90 (2.0)

57 (1.3)

7 (1.5)

50 (1.3)

0.005

COPD

583 (11.3)

76 (14.2)

507 (11.0)

749 (16.8)

116 (24.4)

633 (15.9)

< 0.0001

Any liver disease

580 (11.3)

91 (17.0)

489 (10.6)

415 (9.3)

70 (14.7)

345 (8.7)

0.002

Diabetes

366 (7.1)

38 (7.1)

328 (7.1)

329 (7.4)

51 (10.7)

278 (7.0)

0.60

Renal disease

336 (6.5)

41 (7.6)

298 (6.4)

200 (4.5)

24 (5.0)

176 (4.4)

< 0.0001

Any malignancy

234 (4.5)

31 (5.8)

203 (4.4)

143 (3.2)

28 (5.9)

115 (2.9)

0.001
0.67

Metastatic solid tumor

30 (0.6)

8 (1.5)

22 (0.5)

29 (0.7)

4 (0.8)

25 (0.6)

Hepatitis C infection

633 (12.3)

106 (19.7)

527 (11.4)

436 (9.8)

90 (18.9)

346 (8.7)

Depression

795 (154)

105 (19.6)

690 (14.9)

955 (21.4)

134 (28.2)

821 (20.6)

< 0.0001

Psychotic disorder

329 (6.4)

31 (5.8)

298 (6.5)

297 (6.7)

38 (8.0)

259 (6.5)

0.58

Migraine/headache

< 0.0001

50 (1.0)

6 (1.1)

44 (1.0)

73 (1.6)

8 (1.7)

65 (1.6)

0.004

135 (2.6)

17 (3.2)

118 (2.6)

74 (1.7)

8 (1.7)

66 (1.7)

0.001

43 (0.8)

7 (1.3)

36 (0.8)

62 (1.4)

6 (1.3)

56 (1.4)

0.009

Opportunistic infection

987 (19.2)

116 (21.6)

871 (18.9)

876 (19.6)

118 (24.8)

758 (19.0)

0.54

Alcohol abuse

494 (9.6)

66 (12.3)

428 (9.3)

320 (7.2)

38 (8.10)

282 (7.10)

< 0.0001

Substance use disorder

937 (18.2)

145 (27.0)

792 (17.2)

913 (20.5)

157 (33.0)

756 (19.0)

0.005

Tobacco use disorder

478 (9.3)

61 (11.4)

417 (9.0)

356 (8.0)

48 (10.1)

308 (7.70)

0.02

Back pain

421 (8.2)

88 (16.4)

333 (7.2)

368 (8.3)

64 (13.5)

304 (7.6)

0.88

Neck pain

146 (2.8)

29 (5.4)

117 (2.5)

131 (2.9)

16 (3.4)

115 (2.9)

0.76

1040 (20.2)

164 (30.5)

876 (19.0)

932 (20.9)

144 (30.3)

788 (19.8)

0.38

Neuropathy pain

501 (9.7)

96 (17.9)

405 (8.8)

437 (9.8)

67 (14.1)

370 (9.3)

0.90

Unclassified pain

122 (2.4)

25 (4.7)

97 (2.1)

291 (6.5)

37 (7.8)

254 (6.4)

< 0.0001

Any fracture
Surgery history

Pain-related disorder

Arthritis/ joint pain

Number of medications

< 0.0001

None

1811 (35.1)

148 (27.6)

1663 (36.0)

1724 (38.7)

140 (29.4)

1584 (39.8)

1–4

2773 (53.8)

301 (56.1)

2472 (53.5)

2340 (52.5)

262 (55.0)

2078 (52.2)

570 (11.1)

88 (16.4)

482 (10.4)

396 (8.9)

Non-opioid pain
medication

5+

1087 (21.1)

159 (29.6)

928 (20.1)

1197 (26.8)

74 (15.6)

322 (8.1)

177 (37.2)

1020 (25.6)

Benzodiazepine

530 (10.3)

102 (19.0)

428 (9.3)

Gabapentinoid

330 (6.4)

58 (10.8)

272 (5.9)

409 (9.2)

88 (18.5)

321 (8.1)

0.07

246 (5.5)

56 (11.8)

190 (4.8)

Antidepressant

1249 (24.2)

188 (35.0)

1061 (23.0)

0.07

1301 (29.2)

215 (45.2)

1086 (27.3)

Antipsychotics

623 (12.1)

76 (14.2)

547 (11.9)

619 (13.9)

104 (21.9)

515 (12.9)

Any opioid use

1551 (30.1)

261 (48.6)

1290 (27.9)

1498 (33.6)

254 (53.4)

1244 (31.2)

< 0.0001

< 0.0001
0.01
0.0002

Table 3.  Characteristics of study sample by sex. All results presented are N (%) unless otherwise noted.
Abbreviation COPD, Chronic pulmonary disease. a T-test and Pearson Chi-Square tests were used to assess
differences between male and female beneficiaries. b American Indian, Alaskan Native, Hispanic, Asian, Pacific
Islander, Native Hawaiian, more than one race.
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Figure 2.  Forest plot presenting the predictors (reduced model) of chronic opioid therapy initiation in
female (A) and male (B) Medicaid beneficiaries with patients with HIV. Note Generalized estimating equation
multivariable logistic regressions, accounting for clustering at the state level, were used and the reduced model
was selected by backward selection.
use, back pain, neck pain, arthritis, and unclassified pain; polypharmacy; taking non-opioid pain medication,
benzodiazepine, gabapentinoid, antidepressant, and any opioid). However, dementia (0.92 [0.72, 1.18]), diabetes
(0.69 [0.50, 0.96]), and neuropathic pain (1.62 [1.38, 1.90]) were associated with COT only in males, whereas
COPD (1.25 [0.94, 1.66]), liver disease (0.75 [0.62, 0.90]), malignancy (1.61 [1.25, 2.07]), and antipsychotic
medication (1.19 [1.06, 1.35]) associated with COT only in females (Fig. 2). Although predictors, including
renal disease, surgery history, tobacco use disorder, COPD, neck pain, arthritis, unclassified pain, and use of
gabapentinoid in females; and hypertension, renal disease, any fracture, neck pain, arthritis, use of non-opioid
pain medication, and dementia in males, were not statistically significant in the final model, they were included
due to the improvement of overall fit of the regression model.

Discussion

This study identified patient-related factors associated with initiation of COT in Medicaid beneficiaries with
HIV who initiated cART. The overall prevalence of COT in this study was 10.5% and was higher than a study
conducted by Silverberg et al. (8.0%) using Kaiser Permanente North California in 200519. However, another
cross-sectional study conducted by Merlin et al. reported higher prevalence of COT (17%) than our study2. The
Merlin study included participants with HIV receiving care at the University of Alabama at Birmingham using
patient reported outcome data around 2012. These differences could be due to populations with public insurance
vs. commercial insurance and data from clinic cohort, and the population of this study was restricted to the
beneficiaries with HIV who initiated cART. Also, since there is no standard definition of COT, all of these studies had different definitions for identifying COT. A recent review paper demonstrated that the COT prevalence
varied across studies due to different population and COT definition27. Also, the study conducted by Merlin et al.
used more recent data compared to our study.
In our study, the prevalence of COT was similar between males (10.4%) and females (10.7%). This result is
inconsistent with previous studies that reported women with HIV suffer from more pain6, and that female sex
predicts chronic opioid use in Kaiser Permanente members with HIV19. This could be due to the different populations included in the study-Medicaid beneficiaries in KY, MD, WA, and NC vs. Kaiser Permanente members in
Northern California. However, in our study, the prevalence of COT in WA, which is similar in terms of geography
and environment to Northern California, was not significant but higher in males than in females. Among the
four states, COT prevalence was higher among female beneficiaries only in MD.
We found that Medicaid beneficiaries with HIV in this study had similar prevalence of pain-related symptoms
(back pain, neck pain, arthritis and joint pain, and neuropathic pain) by sex, except higher prevalence of unclassified pain and migraine/headache in females. This result was consistent with a cross-sectional study including
residents with HIV in Uganda reported that female sex was positively associated with headache38. In populations
with similar indications for opioid treatment in males and females, sex differences may be diminished. Therefore,
further studies are needed to examine the nature of sex-specific differences in COT among patients with HIV.
The factors we identified as significantly associated with COT initiation were consistent with other studies. A 2005 study that found that factors, including age 40 to 49 years vs. 18 to 39 years, female sex, a Charlson
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Comorbidity Index score of two or more vs zero, injection drug use history, depression, and substance use disorders, were associated with prevalent COT in Kaiser Permanente members with HIV19. A recent study using
Veterans Aging Cohort Study survey confirmed that people with HIV with escalating opioid use were more likely
to be associated with psychoactive prescribed medications, anxiety symptoms, pain interference, and marijuana
use compared to people with HIV with stable, infrequent opioid u
 se17. The lower rate of COT initiation among
patients with HIV diagnosed with alcohol dependence in this study was also observed from the Merlin s tudy2.
Also, some of the factors associated with COT in the current study also predicted chronic opioid use among
older adults enrolled in studies of brain aging and dementia in the National Alzheimer’s Coordinating Center
database39. Older age; antidepressant, anxiolytic, sedative, or hypnotic agents; and polypharmacy were associated
with COT in both studies39. This raises a concern that patients with higher medical burden (e.g., more comorbidities, taking benzodiazepines, and polypharmacy) are more likely to be on COT within already vulnerable
populations, such as older adults and patients with HIV.
This study showed that polypharmacy was significantly associated with COT in both male and female patients
with HIV. However, since polypharmacy is associated with adverse events (e.g., decreased adherence to ARV and
increased risk of hospitalization and mortality) in patients with HIV40–42, special cautions seem to be needed to
prescribe COT in HIV patients with polypharmacy. Especially, we found that treatment with benzodiazepines or
gabapentinoids was significantly associated with COT initiation in both sexes. The 2016 guideline provided by the
US Centers for Disease Control and Prevention recommend avoiding concurrent use of opioids and benzodiazepines due to the increased risk of fatal o
 verdose26, and recently, the US Food and Drug Administration warned
about the potential risk of respiratory depression in patients using opioids and gabapentin c oncurrently43. Since
our study was conducted well-before these guidelines were released, further studies with more recent data are
needed to investigate the trend of concurrent prescriptions of benzodiazepines and gabapentinoids with COT
and the potential risks associated with COT in patients with HIV who are concurrently using benzodiazepines
or gabapentin.
Most of the comorbidities we assessed were positively associated with COT in patients with HIV, but psychotic disorder was negatively associated in both sexes. In the general population, history of psychotic disorder is
reported to be positively associated with chronic opioid u
 se44,45. However, this association was not observed in our
study of patients with HIV. Because it has been studied that patients with HIV who also have psychotic disorders
tend to have higher stimulant use and mortality r ate46,47, and are positively associated with drug d
 ependence48,
there is a possibility that providers are careful when prescribing opioids chronically in these patients with HIV.
Also, since patients with psychotic disorders have more chance to seek the healthcare p
 rovider49, it is possible
for them to have higher chance of managing pain through non opioid treatment. In contrast, we found that use
of antipsychotic medications was positively associated with COT initiation in women. Having concern that use
of antipsychotic medications has different effects on COT initiation in patients with HIV by sex, future studies
are needed to support our results to conclude that the effect of antipsychotic use on COT initiation in patients
with HIV is different between male and female.
Several studies reported that the patients with HIV with lower CD4 + count and advance disease stage had
higher prevalence of p
 ain50–52. Since we did not have CD4 + counts, we included opportunistic infections which
occur more frequently in people with advanced HIV. However, the results in this study indicated that having
opportunistic infections was a predictor of COT initiation in patients with HIV but was not significant. This
result was consistent to a study conducted by Silverberg et al. which reported that the CD4 + , HIV viral load,
was not significantly associated with long-term opioid use in 2 00519.
There are several strengths and limitations in this study. The vast majority of people included in previous
studies were male (78.8–98%)2,7,8,17,18,53; however, this study was more balanced and included 46.4% of females
which allowed us to assess COT in both sexes. We have several unmeasured potential predictors (e.g., clinician
characteristics, undocumented opioid use, and use of over-the-counter drugs) due to the limitation of prescription claims data. We used opportunistic infection as a proxy for severity of HIV disease as laboratory data were
unavailable. Also, since the recent guidelines of treatment of HIV changed to prescribe cART regardless of CD4
count or viral load, the study sample included in this study will have more severe HIV condition with lower
CD4 + cell counts compared to the recent patients with HIV taking cART. Finally, since this study used Medicaid
data from four states and restricted to the patients with standard cART, the results may not be generalized to the
overall population of patients with HIV.

Conclusions

In conclusion, one in ten Medicaid beneficiaries with HIV initiated COT from 2002 to 2009. More vulnerable
population (e.g., having comorbidities and polypharmacy) were more likely to be associated with COT in patients
with HIV. We found that while multiple predictors of COT were shared between males and females, having diabetes, dementia, and neuropathic pain were male-specific predictors while taking antipsychotic medications; having
COPD, malignancy, and liver disease were female-specific predictors. These sex-specific predictors should be fully
investigated with more recent data when assessing the risk and benefit of COT in patients with HIV. Also, further
studies should investigate the health outcomes associated with prescribing chronic opioids in patients with HIV.

Data availability

The data that support the findings of this study are available from Centers for Medicaid and Medicare Services
but restrictions apply to the availability of these data, which were used under license for the current study, and
so are not publicly available.
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